Effects of novel psychoactive substances on cognition and emotion

  • Research type

    Research Study

  • Full title

    Cognitive and psychological characteristics of consumers of novel psychoactive substances

  • IRAS ID

    233926

  • Contact name

    Barbara Sahakian

  • Contact email

    bjs1001@medschl.cam.ac.uk

  • Sponsor organisation

    University of Cambridge

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    Novel psychoactive substances (NPS; often incorrectly termed 'legal highs' and also 'club drugs') refer to new drugs that are designed to mimic the effects of 'classic' drugs of abuse. In 2016, a blanket ban came into force in the UK, which criminalised the distribution, sale and supply of these substances. However, recent statistics (2015/16) by European, American and UN authorities report that there has been an increase in the availability, use and harmful effects of these substances, particularly in young adult men. The total number of substances detected by enforcement and monitoring agencies rose from 166 in 2009 to more than 560 in 2015 (European Monitoring Centre for Drugs and Drug Addiction, 2016) and the number of presentations in English drug treatment centres rose from 302 in 2013/14 to 2,041 in 2015/6 (NDTMS). Despite this, little is known about the effects of NPS on user's cognitive and social-emotional profile. This study will be conducted at the London Club Drug Clinic (http://clubdrugclinic.cnwl.nhs.uk/), which provides services for people who have begun to experience harms with their recreational drug use. Individuals attending clinic who report frequent NPS use will be asked to complete a single, three-hour session to complete a battery of computerised cognitive testing and interview of their drug use. These tests will help indicate if there are differences in cognitive processes (e.g. attention, memory), as well as social and emotional function (e.g. sensation-seeking, risk-taking) compared with individuals who frequently use NPS, but do not receive support from a clinic, and those who have never used novel or classic drugs. This study will help identify key differences between users and non-users of NPS and their effects of cognition and emotion, which have not yet been identified.

  • REC name

    East of England - Cambridge Central Research Ethics Committee

  • REC reference

    17/EE/0453

  • Date of REC Opinion

    22 Nov 2017

  • REC opinion

    Favourable Opinion